Research on type 2 diabetes and its management. Covers nerve pain, early onset, BMI trajectories, and treatment side effects.
A new study found that dihydropyridine calcium-channel blockers (DCCBs) may be associated with poorer kidney outcomes in people with type 2 diabetes, even among those receiving modern kidney-protective treatments. DCCBs were linked to a higher risk of major adverse kidney events.
A new study reveals how Philip Morris Companies Inc. used cigarette research and flavor engineering to design Lunchables, a successful ultra-processed food for children. The company's strategy was based on optimizing 'technical synergies' between tobacco and food divisions.
The FLOW trial shows that semaglutide significantly improved health-related quality of life in adults with type 2 diabetes and chronic kidney disease. Health utility scores and self-rated general health scores improved with semaglutide, but declined with placebo.
The study found that participants in the 'Healthy Living' online program experienced moderate improvements in their blood sugar levels, blood pressure, and body mass index (BMI). The program was designed to support self-management of type 2 diabetes and showed promising results in England.
Researchers from Pennington Biomedical will showcase their latest findings on prevention, care, and cures for diabetes and obesity at the American Diabetes Association's 2026 Scientific Sessions. The sessions will highlight cutting-edge advancements driving progress in diabetes research and management.
A new model predicts retinal degeneration in diabetics based on 71 plasma proteins. The Pro-DRN model can help doctors identify patients at risk earlier, potentially preventing neurodegeneration and vision loss.
Weight loss after bariatric surgery is associated with better ability to cope with daily household tasks such as cleaning and grocery shopping. The study also found that maintaining weight loss for long periods results in improved functionality and independence. Patients who regained lost weight experienced poorer outcomes over time.
A nationally representative study found a nearly 4-fold increase in type 2 diabetes prevalence among US children and adolescents between 10 to 17 years old. The substantial rise is concerning due to the disease's lifetime risk of severe complications and premature deaths.
Research finds gestational diabetes significantly increases risk of type 2 diabetes in women with normal pre-pregnancy weight. The study, published in eClinicalMedicine, analyzed over 1.15 million Swedish mothers and found elevated blood sugar levels predict future type 2 diabetes.
A new study by UMass Amherst researchers found that lifestyle factors such as body weight, physical activity, and diet play a powerful role in shaping diabetes risk. More than half of new Type 2 diabetes cases could be prevented if people with less healthy lifestyles improve those behaviors.
Researchers are developing a multi-organ model on a chip to study the complex interactions between organs, hormones, and cells in diabetes and dementia. The GlucoBrain project aims to understand how signals move between the brain, gut, and pancreas, potentially leading to new treatments for millions affected by these diseases.
Weight loss followed by weight regain, known as 'yo-yo dieting,' is not supported by strong scientific evidence. The authors found that benefits of losing weight outweigh the theoretical risks of weight cycling in most cases. Repeated attempts at weight loss can provide meaningful periods of improved metabolic health and quality of life.
A nationwide self-controlled cohort study found that GLP-1 class of obesity drugs were associated with a 26% fall in asthma exacerbations and a 14% drop in use of asthma inhaler reliever. The study suggests that weight loss, modulation of airway inflammation, and improvements in metabolic functions may improve asthma outcomes.
Researchers have identified potential mechanisms linked to reduced type 2 diabetes risk in chronic cannabis users. A team led by Nicholas V. DiPatrizio found that specific compounds within cannabis regulate metabolism, leading to significant weight loss and improved glucose regulation in obese mice.
A new international study found that genetic variations in the PAM gene can reduce the effectiveness of GLP-1 receptor medications, such as Ozempic. Researchers discovered that 44% of people with these genetic variants experienced reduced glucose lowering properties, and only 11% achieved recommended glucose levels.
A large-scale Nordic study found a link between PCOS and heart disease, with women at increased risk even in normal weight. The study also highlighted the importance of regular medical screenings for women with PCOS.
A new Northwestern University study finds metformin primarily targets the gut, driving glucose utilization inside cells lining the intestine to prevent blood sugar levels from rising. The drug slows mitochondrial energy production in gut cells, allowing the intestine to metabolize extra sugar and regulate blood sugar levels.
The ECE 2026 brings together researchers and clinicians to share the latest endocrine research and developments. Key sessions include Plenaries, Symposia, Awards, Meet the Experts, Debates, and Oral Communications.
A new study has found that individuals with insulin-requiring type 1 and type 2 diabetes have a significantly higher risk of developing dementia compared to those without diabetes. The study, which examined over 1.3 million adults in South Korea, suggests that dementia risk is not the same for all types of diabetes.
A study by the University of Gothenburg reveals that changes in gut bacteria composition after bariatric surgery are strongly associated with improved glucose metabolism and insulin release. Patients with type 2 diabetes who achieved improved glycemic control exhibited greater microbial gene richness and enhanced fermentation processes.
Researchers at Kyoto University discovered that ATF6α plays a critical role in enabling the survival and proliferation of beta cells under sustained stress, leading to impaired beta cell mass expansion. The study highlights the potential for developing new therapeutic strategies to preserve and restore beta cell mass in diabetes.
A $10 million grant from the National Institute of Environmental Health Sciences will support research on PFAS health effects and translate discoveries into real-world solutions. The study aims to identify links between PFAS exposure and metabolic conditions, such as obesity and type 2 diabetes.
A new review found that GLP-1 weight-loss drugs significantly reduced the risk of heart attacks, strokes, and premature death. The treatment also lowered rates of non-fatal heart attacks, hospital admissions for heart failure, and deaths from any cause.
A new approach for treating obesity and type 2 diabetes has been developed using a hybrid molecule that targets specific cells. The treatment combines the well-known GLP-1/GIP signalling pathway with an additional metabolic modulator, delivering improved blood-glucose values and weight loss.
Researchers mapped epigenome changes in cells that regulate blood sugar levels, finding patterns differ between people with and without type 2 diabetes. Epigenetic alterations impact insulin-producing beta cells, leading to impaired energy production and reduced insulin release.
A major clinical trial found that real-time continuous glucose monitoring significantly improves blood glucose management in adults with type 2 diabetes treated with basal insulin. Participants using CGM showed greater reductions in HbA1c levels compared to traditional finger prick glucose monitoring.
A study of 3,000 Punjabi Sikhs identified new molecular pathways contributing to cardiovascular disease, including a link between lipid metabolites and immune cell signaling. These findings offer insights into diverse molecular origins of cardiometabolic disease and potential pathways for designing innovative therapies.
The European Society of Endocrinology organizes World Hormone Day to educate the public about hormone-related health issues. Global endocrine disorders affect millions worldwide, emphasizing the need for proper hormone balance.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population. Obesity was identified as the strongest independent MRF among Asians, Whites, and Hispanics, particularly in individuals younger than 50 years, whereas hypertension was the strongest independent MRF in Blacks.
A ketogenic diet has been shown to improve beta-cell function in patients with type 2 diabetes by decreasing proinsulin secretion and reducing pancreas stress. This improvement is associated with changes in the proinsulin-C-peptide ratio, a biomarker of pancreas stress.
A recent study from The Jackson Laboratory has identified dozens of unexpected genes strongly linked to type 2 diabetes. These genes are key to cell death and vitamin A metabolism, suggesting the disease depends on expression changes that can be targeted for treatment.
A massive genetic study has uncovered six new genes linked to pregnancy sickness, hyperemesis gravidarum (HG), in over 10,000 women. The findings point to biological mechanisms behind HG and potential new treatment pathways, with several medications identified as potential targets.
A study of over 600,000 people found that early weight gain is associated with a higher risk of dying from various diseases, particularly cardiovascular disease and type 2 diabetes. Weight gain during adulthood also increases the risk of premature death, especially for those who develop obesity at a younger age.
A new study by Stanford Medicine scientists has identified a genetic variant that causes resistance to GLP-1 diabetes drugs in up to 10% of the population. The variant affects an enzyme called PAM, which handicaps the hormone's biological activity, leading to increased levels but reduced effectiveness.
A new study uses an AI model to predict type 2 diabetes risk based on behavioral and psychosocial information. The digital twin model found that loneliness, insomnia, and poor mental health substantially raise a person's future risk of developing the disease.
Research published in Ethnicity & Disease found that self-employed Hispanic women report less high blood pressure, obesity, and poor health compared to their salaried counterparts. They were also more likely to exercise, with a nearly 11% higher rate of physical activity.
A preclinical study found that short-term high-fat diet exposure rapidly depletes critical gut immune cells called ILC3s, leading to intestinal permeability and inflammation. The loss of these cells compromises intestinal barrier function and may contribute to chronic diseases linked to inflammation.
A $35 monthly insulin out-of-pocket cap is associated with significantly lower insulin costs, increased access to insulin, and decreased blood glucose levels among Medicare beneficiaries. This finding suggests that federal cost-sharing policies could improve access to essential medications in diabetes.
A new study found that adults with obstructive sleep apnea have a 71% higher risk of cardiovascular events or death from any cause compared to those without the condition. People with OSA also experience higher rates of obesity, diabetes, osteoarthritis, anxiety, and depression.
A lower semaglutide price could generate savings that offset the cost of treating an additional 550,000 to 3.6 million Medicare beneficiaries eligible for expanded obesity-indication coverage. This voluntary price agreement may lead to substantial savings for Medicare spending on semaglutide treatment.
Researchers found a clear connection between oral health and kidney health, with immune dysregulation and systemic inflammation driving the relationship. The study highlights the need for physicians to integrate oral and renal health into clinical care systems.
A team from SickKids discovered a therapeutic target in fat tissue that improves cellular function and reduces inflammation. Low-dose homoharringtonine treatment selectively eliminates senescent cells, improving metabolic problems and preserving lean mass.
Researchers found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide reported improved emotional responses and a greater quality of life. The study suggests that tirzepatide may offer broader benefits beyond glucose control, improving patients' physical and emotional well-being.
A study by IBEC reveals how thousands of amylin mutations influence its tendency to form toxic aggregates in the pancreas, linked to type 2 diabetes. The researchers created a mutational map using deep mutational scanning, identifying variations that promote or hinder amyloid formation.
A review highlights the importance of healthy lifestyles in reducing the risk of cardiovascular disease and type 2 diabetes. Adhering to optimal lifestyle factors, such as a heart-healthy diet, regular physical activity, and adequate sleep, can dramatically lower disease incidence.
The Endocrine Society supports the INSULIN Act to address insulin affordability, setting a $35 monthly cap for people with private insurance and creating a program for uninsured individuals. The bill aims to reduce insulin prices by encouraging competition in the market.
A recent study found that people with a high genetic predisposition to type 2 diabetes are increasingly developing the disease, possibly due to societal changes such as easy access to unhealthy foods and sedentary leisure activities. In contrast, individuals with low genetic risk remained protected throughout the study period.
A new algorithm paired with a continuous glucose monitor can help users better manage their type 2 diabetes by recommending insulin-dose adjustments. Participants who used the algorithm saw significant improvements in time spent in a safe blood-sugar range.
A new study published in JAMA Pediatrics finds that children with obesity but without metabolic complications still face a significantly increased risk of developing type 2 diabetes, high blood pressure, and abnormal blood lipid levels later in life. Treatment can greatly benefit these children, reducing the risk of future diseases.
Children with metabolically healthy obesity at treatment initiation have an increased risk of type 2 diabetes, hypertension, and dyslipidemia. Reduction in BMI z score is associated with reduced cardiometabolic risk, suggesting treatment should be recommended for these children as well.
A study found that inflammation markers may signal depression in women with type 2 diabetes, but vary based on depression symptoms and measures. The research suggests a path toward precision mental health by identifying specific inflammatory biomarkers linked to different dimensions of mental health.
Researchers developed a comprehensive genetic risk calculator for metabolic disease by integrating genetic data from hundreds of thousands of people worldwide. The polygenic risk score outperformed existing disease-prediction models and predicted downstream morbidity and clinical interventions, particularly in non-European populations.
A Cleveland Clinic analysis of nearly 8,000 patients found that discontinuing semaglutide and tirzepatide does not lead to significant weight regain in clinical practice. Many patients successfully stabilized their weight after one year through alternative treatments and therapeutic lifestyle interventions.
A $3.4 million NIH grant will fund a semi-automated feedback system to support people tracking diet, exercise, and weight in weight-management programs. The system aims to provide personalized feedback to increase tracking and weight loss success.
Patients with type 2 diabetes and brain metastases who used GLP-1 receptor agonists showed a significant reduction in all-cause mortality. The use of these medications was associated with reduced neuroinflammation, preservation of the blood-brain barrier, and lowered oxidative stress and mitochondrial dysfunction.
PsyMetRiC, a new web-based risk prediction tool, forecasts cardiometabolic disorders in young people with psychosis. The algorithm predicts significant weight gain, metabolic syndrome, and type 2 diabetes within specific time frames, enabling meaningful discussions and interventions.
Analysis of unintended side effect reports reveals that Wegovy carries the highest risk of 'eye stroke' and sudden sight loss among semaglutide drugs, with odds nearly 5 times higher than Ozempic. The risk is particularly pronounced in men, with a signal nearly 3 times higher than in women.
Researchers mapped GLP-1 expression in 25 brain regions in each sex, uncovering striking differences in key circuits. The atlas reveals sex-biased expression in certain medullary nuclei, with higher Glp1 densities and numbers of Glp1-expressing neurons in females compared to males.
Women with cardiometabolic risk factors such as type 2 diabetes and high waist circumference face a higher risk of liver fibrosis, with rates increasing 11-fold and 2.8-fold compared to men. The study highlights the importance of managing these risk factors for liver health beyond heart disease prevention.
A novel plant-based approach uses lettuce chloroplasts to produce functional GLP-1 peptides, paving the way for more affordable and better-tolerated oral medications. This method bypasses hurdles such as manufacturing cost, delivery system, and side effects associated with conventional approaches.